58.3% MRD Clearance in Phase 2 ALPHA3 Trial Bolsters Allogene’s 2029 Cash Runway
ALLO•Interim futility analysis of the Phase 2 ALPHA3 trial showed 58.3% of patients in the cema-cel arm achieved MRD clearance versus 16.7% in observation, with a median ctDNA reduction of 97.7% and no serious adverse events. Allogene closed Q1 with $266.9 million cash and raised $200.4 million in April, extending its runway into Q1 2029.
1. Interim ALPHA3 Trial Results
In a planned futility analysis of the pivotal Phase 2 ALPHA3 trial, 7 of 12 patients (58.3%) receiving cemacabtagene ansegedleucel achieved MRD negativity at Day 45 versus 2 of 12 (16.7%) in the observation arm, representing a 41.6% absolute increase in clearance. Median ctDNA levels fell by 97.7% in the cema-cel group compared with a 26.6% median increase in control, indicating robust early efficacy.
2. Favorable Safety and Outpatient Potential
Cema-cel demonstrated a clean safety profile with no cytokine release syndrome, neurotoxicity, graft-versus-host disease or treatment-related serious adverse events, enabling most infusions in outpatient and community cancer center settings. Approximately one-third of screening and infusion activities occurred at centers new to CAR T therapy, highlighting potential for broader community uptake.
3. Cash Runway Extended Through 2029
Allogene ended Q1 with $266.9 million in cash, cash equivalents and investments, and its April public offering added $200.4 million gross, securing funding into the first quarter of 2029. This financial strength underpins continued enrollment in ALPHA3, global site activation and advancement of the Phase 1 RESOLUTION trial.
4. Overland Partnership Terminated and Equity Reworked
The company has ended its cell therapy development partnership in Greater China with Overland Therapeutics and restructured its equity stake in that collaborator. This move refocuses Allogene’s strategic resources on core clinical programs and global regulatory efforts.
